Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer
Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors
OSS, The Netherlands--(BUSINESS WIRE)--Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. CIT-013 is a first in class humanized therapeutic antibody targeting Neutrophil Extracellular Trap (NET) formation and clearance. CIT-013 is being developed for autoimmune and chronic inflammatory diseases and other indications where NETs play an important role in pathogenesis.